Alan Craig Vawdrey
Land Surveyors in Riverton, UT
License number
Utah 4777890-E202
Category
Engineer/Land Surveyor
Type
Engineer Exam - Obsolete
Address
Address
Riverton, UT
Personal information
See more information about Alan Craig Vawdrey at radaris.comName
Address
Phone
13890 Lookout Peak Dr, Riverton, UT 84096
1009 460 S, Provo, UT 84606
13890 Lookout Peak Dr, Herriman, UT 84065
Professional information
Transdermal Drug Delivery With Controlled Heat For Treating Musculoskeletal Pain And/Or Inflammation
US Patent:
2008022, Sep 18, 2008
Filed:
Feb 28, 2008
Appl. No.:
12/074259
Inventors:
Jie Zhang - Salt Lake City UT, US
Kevin S. Warner - West Jordan UT, US
Randal Nelson - West Jordan UT, US
Alan Vawdrey - Riverton UT, US
Nathan Strong - Sandy UT, US
Suyi Niu - Salt Lake City UT, US
Michael D. Wessman - Salt Lake City UT, US
Matthew Iverson - Salt Lake City UT, US
Kevin S. Warner - West Jordan UT, US
Randal Nelson - West Jordan UT, US
Alan Vawdrey - Riverton UT, US
Nathan Strong - Sandy UT, US
Suyi Niu - Salt Lake City UT, US
Michael D. Wessman - Salt Lake City UT, US
Matthew Iverson - Salt Lake City UT, US
International Classification:
A61F 7/08, A61K 9/00, A61K 31/192, A61K 31/196, A61K 31/167
US Classification:
604290, 424449, 514570, 514567, 514626, 604291
Abstract:
Systems and methods for transdermal drug delivery with controlled heat are provided. Such systems can comprise a heating apparatus that includes an exothermic chemical composition, typically in the form of individual heating elements. The heating apparatus can be exposed to ambient oxygen through a cover. The cover can reduce the amount of ambient oxygen capable of contacting the chemical composition compared to when the cover is not present. In some embodiments, the heating apparatus can include more than one heating element. The systems can further include a drug-containing layer that includes a drug. The drug-containing layer can have a surface area of about 50 cmto about 400 cm. The systems of the present invention can be deliver ketoprofen in an amount sufficient to produce a mean blood plasma concentration of ketoprofen in a human subject of at least 45 ng/ml within four hours after initial application of the system to a skin surface.